Abbott Laboratories
—- Market cap
- $177.58B
- Debt
- —
- Cash
- −$8.52B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $177.58B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
Decision snapshot: ABT stock price at premium vs GILD $101.95 current versus $78.86 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GILD's multiple
Implied fair value · at ABT's multiple
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Johnson & Johnson
ABT vs JNJ
Medtronic plc
ABT vs MDT
BECTON DICKINSON & CO
ABT vs BDX
Thermo Fisher Scientific Inc.
ABT vs TMO
DANAHER CORP /DE/
ABT vs DHR
BOSTON SCIENTIFIC CORP
ABT vs BSX
AbbVie Inc.
ABT vs ABBV
AMGEN INC
ABT vs AMGN
BRISTOL MYERS SQUIBB CO
ABT vs BMY
Merck & Co., Inc.
ABT vs MRK
PFIZER INC
ABT vs PFE
REGENERON PHARMACEUTICALS, INC.
ABT vs REGN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABT can sustain its faster revenue growth while improving margins toward GILD levels, then hold or accumulate because the balance sheet is stronger than GILD's and the current multiple is not extreme on a sales basis; if not, the current price appears stretched relative to the implied and DCF ranges.
ABT trades at a higher P/E than GILD but a lower P/S, while both names sit at the same EV/EBITDA multiple, so the relative valuation picture is inconsistent rather than uniformly cheap or expensive. The implied price of $70.77 suggests an 18.9% downside from the current price of $87.25, although GILD-implied range and historical band both overlap around the current level.
Supporting Metrics